What Are the Long Term Side Effects of Exemestane?

Exemestane, sold under the brand name Aromasin, can cause several lasting side effects that stem from its core action: dramatically lowering estrogen levels in postmenopausal women. The most well-documented long-term effects include accelerated bone loss, joint and muscle pain, unfavorable shifts in cholesterol, and vaginal dryness or sexual difficulties. Cardiovascular risk and body composition changes round out the list of concerns that women and their oncologists weigh against the drug’s proven ability to reduce breast cancer recurrence. The picture, though, is more nuanced than a simple catalog of harms, and exemestane’s side-effect profile differs in meaningful ways from the other drugs in its class.

A Quick Note on How Exemestane Works

Exemestane belongs to a group of drugs called aromatase inhibitors (AIs), which block the enzyme responsible for producing estrogen in postmenopausal women. What sets exemestane apart is that it permanently disables the aromatase enzyme rather than temporarily blocking it, earning it the label “irreversible” or “suicidal” inhibitor.¹ That distinction matters because it means the body has to manufacture entirely new enzyme molecules to resume estrogen production. The practical result is estrogen levels that drop to nearly undetectable levels, which is the whole point for fighting hormone-receptor-positive breast cancer, but also the root cause of virtually every long-term side effect discussed below.²

Bone Loss and Fracture Risk

Estrogen is one of the main guardians of bone density in women, so stripping it away accelerates the natural bone-thinning process that follows menopause. The Intergroup Exemestane Study (IES), one of the largest trials to track this, found that women who switched from tamoxifen to exemestane lost roughly 2.7% of bone mineral density at the lumbar spine and about 1.4% at the hip within the first six months.³ The reassuring part of that same study: bone loss slowed considerably after the first six months, dropping to about 1% per year at the spine and under 1% at the hip in the second year. And no woman who started the trial with normal bone density went on to develop osteoporosis during follow-up.

A German substudy within the TEAM trial confirmed a similar pattern, with bone loss mostly front-loaded in the first six months and then stabilizing.⁴ Still, the fracture numbers tell a real story: over about five years in the IES, 7% of women on exemestane experienced a fracture compared with 5% on tamoxifen, a statistically significant difference.³ That gap needs context, though: tamoxifen actually protects bone in postmenopausal women, so part of the difference reflects tamoxifen’s benefit rather than exemestane being uniquely damaging. The trial investigators noted that the improved survival exemestane delivered came “at the expense of some detriment to skeletal health,” a trade-off that needs individual assessment.

Joint Pain and Musculoskeletal Symptoms

Joint and muscle pain is the side effect that drives the most women to quit aromatase inhibitor therapy altogether. Roughly half of patients report new or worsening joint pain within a year of starting treatment, and the discomfort can affect hands, wrists, knees, hips, and the lower back.⁵ The pain tends to peak in the first several months and, for many women, gradually eases somewhat but never fully resolves while they remain on the drug. It is worth noting that this side effect is not unique to exemestane; all three aromatase inhibitors cause it, and the underlying mechanism appears tied directly to estrogen depletion’s effects on joint tissue and fluid.

The practical toll is substantial. About 30% of patients stop aromatase inhibitor therapy within the first year, and only about half to two-thirds remain fully compliant after three years, with musculoskeletal pain being the most frequently cited reason for stopping early.⁵ Exercise, particularly moderate aerobic activity and strength training, has the strongest evidence for easing these symptoms, though anti-inflammatory medications, acupuncture, and vitamin D supplementation are also used. Some women who cannot tolerate one AI find switching to another, including switching from a nonsteroidal AI to exemestane, reduces their pain.

Cholesterol and Lipid Changes

Estrogen helps maintain a favorable cholesterol balance, so suppressing it raises the question of what happens to blood lipids over years of exemestane use. A meta-analysis of randomized trials found that exemestane modestly raises LDL (“bad”) cholesterol by about 4 mg/dL and lowers HDL (“good”) cholesterol by about 6 mg/dL.⁶ Total cholesterol actually dipped slightly, and triglycerides fell in studies lasting less than a year but not in longer ones. These are small shifts individually, but an LDL nudge upward combined with an HDL nudge downward is the unfavorable direction for heart disease risk.

The picture is complicated, though, because much of the comparative data pits exemestane against tamoxifen, and tamoxifen itself has a strong cholesterol-lowering effect. When an earlier review examined exemestane on its own terms, it concluded the drug either had little effect on lipids or was associated with slightly improved profiles compared with what you might expect from estrogen deprivation.⁷ Exemestane has mild androgenic properties that the nonsteroidal AIs lack, and this may partly offset the lipid damage caused by estrogen loss. The Greek TEAM substudy found the overall atherogenic risk ratio stayed stable in both the exemestane and tamoxifen groups throughout the study period.⁸

Cardiovascular Concerns

Lipid shifts feed into a broader worry about heart health. A large population-based cohort study found that aromatase inhibitors were associated with higher rates of heart attack and ischemic stroke compared with tamoxifen, though neither difference was statistically definitive.⁹ A separate retrospective study found that AI use for four or more years was linked to significantly increased risk of arrhythmias and ischemic heart disease.¹⁰ The duration finding is important: short courses may carry less cardiac risk than the five-year or longer regimens that are standard today.

Laboratory research has begun to sketch out why the heart might be vulnerable. A recent study found that chronic exemestane exposure disrupted calcium handling in heart cells and damaged the blood vessel lining, leading to dose-dependent cardiac dysfunction including changes in heart wall thickness and chamber size.¹¹ While this is preclinical work and does not directly translate to human patients, it suggests that cardiac monitoring during prolonged therapy is warranted, particularly for women who already have cardiovascular risk factors.

Cognitive Function and Mood

Many women on hormonal therapy report “brain fog,” but the research on exemestane specifically is more reassuring than you might expect. Two separate studies, including the IBIS-II and TEAM cognitive substudies, found no statistically significant effect of exemestane alone on cognitive performance compared with placebo or healthy controls.¹² In contrast, tamoxifen was consistently linked to worse verbal memory, executive function, and processing speed. A more recent study found that women who took tamoxifen first and then switched to exemestane (a common treatment sequence) did show cognitive decline, but the decline appeared tied to the tamoxifen portion of the sequence rather than the exemestane phase.¹³

This does not mean exemestane is entirely innocent on the brain front. Self-reported cognitive complaints are common across all AIs, and the gap between what women experience subjectively and what formal testing detects is a known issue in this field. Insomnia, which was clinically worse in women on exemestane than on tamoxifen in the TEAM quality-of-life study, can itself impair cognitive function and mood.¹⁴ Fatigue and dyspnea were also reported more often with exemestane than tamoxifen in that study.

Sexual Health and Vaginal Symptoms

Vaginal dryness and loss of libido are among the most persistent and underreported long-term consequences of aromatase inhibitor therapy.¹⁵ Because estrogen plays a direct role in maintaining vaginal tissue health and lubrication, the near-complete estrogen suppression caused by exemestane can lead to vaginal atrophy, pain during intercourse, and reduced sexual desire. In the TEXT and SOFT trials, which studied premenopausal women receiving ovarian suppression along with either exemestane or tamoxifen, those assigned exemestane reported significantly more vaginal dryness, greater loss of sexual interest, and more difficulty becoming aroused.¹⁶

These symptoms often worsen over time rather than improving, and many women find them more distressing than the musculoskeletal pain that gets more clinical attention. Non-hormonal vaginal moisturizers and lubricants are the first-line approach, since systemic estrogen therapy is generally off limits for hormone-receptor-positive breast cancer survivors. Low-dose vaginal estrogen is sometimes discussed on a case-by-case basis, but this remains controversial because even small amounts of estrogen could theoretically feed residual cancer cells.

Body Composition Changes

Weight gain and shifts in body composition are common complaints during AI therapy, but exemestane’s effect here appears somewhat different from what you might expect. One study found that women who switched from tamoxifen to exemestane actually lost fat mass over 12 months, and their ratio of lean mass to fat mass improved, a pattern not seen in women who stayed on tamoxifen.¹⁷ This may relate to exemestane’s mild androgenic activity, which could help preserve or build lean tissue.

However, a broader look at AI therapy in general paints a less rosy picture. A study tracking body composition across the full course of AI treatment found that fat mass increased by roughly 8 to 10% while lean mass dropped by about 3%, and the proportion of patients meeting criteria for sarcopenia and obesity both rose over time.¹⁸ Dietary counseling in that study did not significantly change the trajectory, suggesting that these body composition shifts are driven more by hormonal changes than by eating habits alone. Resistance exercise and adequate protein intake are commonly recommended strategies, though the evidence on how much they can truly counteract AI-driven body changes remains limited.

How Exemestane Compares to the Other Aromatase Inhibitors

Exemestane shares a drug class with anastrozole (Arimidex) and letrozole (Femara), but there are real differences in side-effect profiles. A large 2025 study published in JAMA Network Open compared all three drugs head-to-head and found that the five-year risk of bone fracture was essentially the same: about 4.5% for exemestane versus 4.7% for both anastrozole and letrozole.¹⁹ A network meta-analysis focusing specifically on bone safety found that exemestane showed lower odds of bone pain, fractures, and osteoporosis than either anastrozole or letrozole, though none of the differences reached statistical significance.²⁰

For dyslipidemia, the JAMA study found five-year rates of roughly 15.5% for exemestane, 16% for anastrozole, and nearly 17% for letrozole, a slight advantage for exemestane that again aligns with its androgenic properties potentially buffering lipid damage.¹⁹ On the other hand, the risk of diabetes was slightly higher with exemestane (9.0%) than with anastrozole (8.0%) in that same study. These are differences of a percentage point or two, and individual risk factors probably matter more than which specific AI is chosen.

Perhaps the most practically useful finding is that switching from a nonsteroidal AI to exemestane can reduce the severity of menopausal symptoms. In one study, about half of patients who switched reported a meaningful decrease in symptom severity, with improvements across joint pain, hot flashes, and body aches.²¹ This switching strategy is now widely used in clinical practice when a woman cannot tolerate her first AI.

What Happens With Longer Treatment

Standard adjuvant AI therapy lasts five years, but oncologists increasingly consider extending treatment to seven, eight, or even ten years for women at higher risk of late recurrence. Longer therapy means longer exposure to side effects, and the data here are clear: more time on an AI means more bone damage. A trial comparing five years of AI therapy with two years found a 35% higher risk of clinical fracture in the longer-duration group.²² A large patient-level meta-analysis echoed this, showing that five additional years of AI therapy after an initial five years of endocrine treatment raised the five-year fracture risk from about 3.4% to 4.6%.²³

The cardiovascular data mentioned earlier, showing higher risk of arrhythmias and ischemic heart disease with four or more years of AI use, adds another dimension to the duration question. Extended therapy offers a modest reduction in late recurrences, but the cumulative side-effect burden grows steadily. This is a conversation that each woman should have with her oncologist, factoring in her individual recurrence risk, bone density, cardiac health, and how well she tolerates the drug day to day.

Exemestane Versus Tamoxifen on Specific Organs

For women choosing between exemestane and tamoxifen, the side-effect profiles diverge in predictable ways. Tamoxifen, which works by blocking estrogen receptors rather than eliminating estrogen, tends to cause more hot flashes, sweats, vaginal discharge, and thickening of the uterine lining.¹⁶ Exemestane, by contrast, tends to cause more bone and joint pain, vaginal dryness, and sexual dysfunction. Tamoxifen’s effect on the uterus is particularly relevant: in the IES, nearly two-thirds of tamoxifen patients had abnormal endometrial thickness versus about a third of those who switched to exemestane, and that difference appeared within six months of the switch.²⁴ This matters because tamoxifen carries a small but real risk of endometrial cancer, a risk exemestane does not share.

Adherence and the Side-Effect Burden

The cumulative weight of these side effects has a real impact on whether women finish their prescribed course of treatment. In the MA.27 trial, which compared exemestane and anastrozole head-to-head, 20% of patients in both groups had stopped therapy by two years, and 32% had stopped by four years.²⁵ The strongest predictor of early discontinuation was not any specific side effect but rather how much overall side-effect bother women reported even before starting treatment. Women who entered the trial already sensitive to treatment-related symptoms were significantly more likely to quit. Overall quality of life stayed stable over time in both drug groups, but the burden of individual symptoms was real and cumulative.

In the MAP.3 prevention trial, which tested exemestane in healthy postmenopausal women at increased breast cancer risk, adverse events were reported by 88% of the exemestane group compared with 85% on placebo. Yet there were no significant differences in fractures, cardiovascular events, or deaths between the two groups, and quality-of-life differences were described as minimal.²⁶ That relatively clean safety profile in a prevention setting, where women were generally healthier than cancer patients, suggests that some of the side-effect burden attributed to exemestane in adjuvant trials may reflect the combined effects of cancer treatment itself rather than exemestane alone.

Exemestane’s Mild Androgenic Activity

One detail that comes up across several of these side-effect categories is exemestane’s unique androgenic character. Because it is a steroidal compound structurally related to the body’s own androgens, it and its metabolites can weakly activate androgen receptors. This is not shared by anastrozole or letrozole, which are nonsteroidal molecules. The androgenic activity appears to partly explain why exemestane may be slightly gentler on bones, slightly friendlier to lipid profiles, and capable of reducing fat mass in some studies. It may also explain why switching from a nonsteroidal AI to exemestane helps some women with menopausal symptoms. The trade-off is that this same androgenic effect could contribute to the slightly higher diabetes risk seen in some data, since androgens can influence insulin sensitivity. For a drug that women take for years, even subtle hormonal properties ripple across multiple organ systems in ways that researchers are still untangling.